You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

At high risk of recurrence

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023

Clinical Research of Drug Holiday Based on MRD Detection in GIST

Recruiting
  • Gastrointestinal Stromal Tumors
    • Beijing, Beijing, China
      Peking University People's Hospital
    May 11, 2023

    Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

    Recruiting
    • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
    • Shanghai, Shanghai, China
      Zhongshan Hospital, Fudan University
    Jan 4, 2023

    Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)

    Not yet recruiting
    • Triple Negative Breast Cancer
    • Residual Disease
    • (no location specified)
    Nov 15, 2023

    Kidney Stone Trial in Montréal (Ure-Na)

    Withdrawn
    • Kidney Stone
    • Montréal, Quebec, Canada
      Centre Hospitalier de l'Université de Montréal (CHUM)
    Nov 22, 2022

    Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))

    Recruiting
    • Cholangiocarcinoma, Intrahepatic
    • Shanghai, China
      Lulu@Huashan.Org.Cn
    Aug 16, 2022

    Gastric Cancer Trial in Krakow (FLOT4 + HIPEC + Surgery, FLOT4 + Surgery)

    Recruiting
    • Gastric Cancer
    • FLOT + HIPEC + Surgery
    • FLOT + Surgery
    • Krakow, Lesser Poland Voivodship, Poland
      Department of General, Oncological, Gastroenterological Surgery
    Nov 9, 2022

    Digital Droplet PCR in Early Period After Allo-HSCT to Predict

    Completed
    • Measurable Residual Disease
    • Digital Droplet PCR
    • Hangzhou, Zhejiang, China
      The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
    Aug 17, 2023

    Malignant Solid Tumor Trial in Nashville (Ifetroban Sodium, Placebo)

    Recruiting
    • Malignant Solid Tumor
    • Ifetroban Sodium
    • Placebo
    • Nashville, Tennessee
      Vanderbilt-Ingram Cancer Center
    Jun 23, 2022

    Hepatocellular Carcinoma, TACE, Anlotinib Trial in Lanzhou, Xi'an (Anlotinib Hydrochloride, TACE)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Anlotinib Hydrochloride
    • TACE
    • Lanzhou, Gansu, China
    • +3 more
    Jan 12, 2023

    Hepatocellular Carcinoma Trial in Hangzhou (Anlotinib Hydrochloride)

    Terminated
    • Hepatocellular Carcinoma
    • Anlotinib Hydrochloride
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital of Medical School of Zhejiang Univ
    Aug 25, 2022

    Hepatocellular Carcinoma Trial in Hefei (Tislelizumab + Sitravatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • Tislelizumab + Sitravatinib
    • Hefei, Anhui, China
      Anhui province hospital
    Jul 27, 2022

    Esophageal Squamous Cell Carcinoma Trial in Taipei City (Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Taipei City, Taiwan
      National Taiwan University Hospital
    Jun 5, 2022

    Biliary Tract Cancer, Cholangiocarcinoma Trial in Italy (Gemcitabine, Nab paclitaxel, Cisplatin)

    Not yet recruiting
    • Biliary Tract Cancer
    • Cholangiocarcinoma
    • Ancona, Italy
    • +18 more
    Sep 16, 2023

    Liver Tumors Trial in Beijing (Tislelizumab plus tyrosine kinase inhibitor)

    Recruiting
    • Liver Neoplasms
    • Tislelizumab plus tyrosine kinase inhibitor
    • Beijing, Beijing, China
      302 Hospital
    Sep 22, 2023

    Hepatocellular Carcinoma, Adjuvant Therapy Trial in Changsha (TQB2450 injection, Anlotinib HCl capsules)

    Recruiting
    • Hepatocellular Carcinoma
    • Adjuvant Therapy
    • TQB2450 injection
    • Anlotinib hydrochloride capsules
    • Changsha, Hunan, China
      Hunan Provincial People's Hospital (The First Affiliated Hospita
    Apr 28, 2022

    Esophageal Cancer Trial (OBI-833/OBI-821)

    Recruiting
    • Esophageal Cancer
    • OBI-833/OBI-821
    • Taipei, Taiwan
      National Taiwan University Hospital
    Sep 22, 2022

    Hepatocarcinoma Trial in Shanghai (HAIC+TQB2450+Anlotinib)

    Recruiting
    • Hepatocarcinoma
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Mar 27, 2022

    Hepatocellular Carcinoma (HCC) Trial in Beijing (Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE))

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Expanded Activated Lymphocytes (EAL)
    • transarterial chemoembolization (TACE)
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Feb 4, 2022

    Melanoma Trial in New York (DC Vaccine, Montanide Vaccine, Poly-ICLC)

    Completed
    • Melanoma
    • DC Vaccine
    • +2 more
    • New York, New York
    • +1 more
    Sep 13, 2022

    Diabetes, Peripheral Neuropathy, Diabetic Foot Trial (Orpyx SI Sensory Insole System)

    Not yet recruiting
    • Diabetes
    • +3 more
    • Orpyx SI Sensory Insole System
    • (no location specified)
    Jul 11, 2023

    Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in Atlanta, Chicago, Philadelphia (Pembrolizumab, Placebo)

    Active, not recruiting
    • Head and Neck Cancer
    • Squamous Cell Carcinoma of the Head and Neck
    • Atlanta, Georgia
    • +3 more
    Apr 13, 2022

    COPD, Lung Non-Small Cell Carcinoma, Pneumonia Trial in Buffalo (Quality-of-Life Assessment, Questionnaire Administration,

    Recruiting
    • Chronic Obstructive Pulmonary Disease
    • +7 more
    • Quality-of-Life Assessment
    • +2 more
    • Buffalo, New York
      Roswell Park Cancer Institute
    Oct 20, 2022

    Hepatocellular Carcinoma, Adjuvant Therapy Trial in Hangzhou (Tislelizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • Adjuvant Therapy
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, School of Medicine, Zhejiang Univ
    Jan 4, 2022

    Multiple Myeloma, Lymphoma Trial in Washington, Hackensack (Ipilimumab, Nivolumab)

    Active, not recruiting
    • Multiple Myeloma
    • Lymphoma
    • Washington, District of Columbia
    • +1 more
    Dec 2, 2021